222 related articles for article (PubMed ID: 25890501)
1. Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.
Gupta J; Igea A; Papaioannou M; Lopez-Casas PP; Llonch E; Hidalgo M; Gorgoulis VG; Nebreda AR
Oncotarget; 2015 Apr; 6(11):8539-51. PubMed ID: 25890501
[TBL] [Abstract][Full Text] [Related]
2. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
[TBL] [Abstract][Full Text] [Related]
3. Triterpenes from Ganoderma Lucidum induce autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase (p38 MAPK).
Thyagarajan A; Jedinak A; Nguyen H; Terry C; Baldridge LA; Jiang J; Sliva D
Nutr Cancer; 2010; 62(5):630-40. PubMed ID: 20574924
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of mitogen-activated protein kinases in human colon cancers.
Wang Q; Ding Q; Dong Z; Ehlers RA; Evers BM
Anticancer Res; 2000; 20(1A):75-83. PubMed ID: 10769637
[TBL] [Abstract][Full Text] [Related]
5. BMP9/p38 MAPK is essential for the antiproliferative effect of resveratrol on human colon cancer.
Yuan SX; Wang DX; Wu QX; Ren CM; Li Y; Chen QZ; Zeng YH; Shao Y; Yang JQ; Bai Y; Zhang P; Yu Y; Wu K; Sun WJ; He BC
Oncol Rep; 2016 Feb; 35(2):939-47. PubMed ID: 26555012
[TBL] [Abstract][Full Text] [Related]
6. Diterpenoid C of Radix Curcumae: an inhibitor of proliferation and inducer of apoptosis in human colon adenocarcinoma cells acting via inhibiting MAPK signaling pathway.
Shen Y; Lu B; Zhang S; Ma ZJ
Pharm Biol; 2014 Sep; 52(9):1158-65. PubMed ID: 24646305
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis induction by p38 MAPK inhibitor in human colon cancer cells.
Tsuchiya T; Tsuno NH; Asakage M; Yamada J; Yoneyama S; Okaji Y; Sasaki S; Kitayama J; Osada T; Takahashi K; Nagawa H
Hepatogastroenterology; 2008; 55(84):930-5. PubMed ID: 18705300
[TBL] [Abstract][Full Text] [Related]
8. IL-32γ enhances TNF-α-induced cell death in colon cancer.
Park ES; Yoo JM; Yoo HS; Yoon DY; Yun YP; Hong J
Mol Carcinog; 2014 Feb; 53 Suppl 1():E23-35. PubMed ID: 23255489
[TBL] [Abstract][Full Text] [Related]
9. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment.
Yang SY; Miah A; Sales KM; Fuller B; Seifalian AM; Winslet M
Int J Oncol; 2011 Jun; 38(6):1695-702. PubMed ID: 21424124
[TBL] [Abstract][Full Text] [Related]
11. Tectoridin inhibits the progression of colon cancer through downregulating PKC/p38 MAPK pathway.
Xiong L; Guo W; Yang Y; Gao D; Wang J; Qu Y; Zhang Y
Mol Cell Biochem; 2021 Jul; 476(7):2729-2738. PubMed ID: 33683556
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells.
Munoz L; Yeung YT; Grewal T
Cancer Biol Ther; 2016 Apr; 17(4):355-63. PubMed ID: 26794430
[TBL] [Abstract][Full Text] [Related]
13. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells.
Tammali R; Ramana KV; Singhal SS; Awasthi S; Srivastava SK
Cancer Res; 2006 Oct; 66(19):9705-13. PubMed ID: 17018629
[TBL] [Abstract][Full Text] [Related]
14. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Delire B; Stärkel P
Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
[TBL] [Abstract][Full Text] [Related]
15. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.
Chang HL; Wu YC; Su JH; Yeh YT; Yuan SS
J Pharmacol Exp Ther; 2008 Jun; 325(3):841-9. PubMed ID: 18337475
[TBL] [Abstract][Full Text] [Related]
16. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor.
Westra J; Doornbos-van der Meer B; de Boer P; van Leeuwen MA; van Rijswijk MH; Limburg PC
Arthritis Res Ther; 2004; 6(4):R384-92. PubMed ID: 15225374
[TBL] [Abstract][Full Text] [Related]
17. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Wong TW; Kramer RA; Wild R; Lee FY
Clin Cancer Res; 2005 Aug; 11(15):5558-65. PubMed ID: 16061873
[TBL] [Abstract][Full Text] [Related]
18. 3,3'-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells.
Khwaja FS; Wynne S; Posey I; Djakiew D
Cancer Prev Res (Phila); 2009 Jun; 2(6):566-71. PubMed ID: 19470787
[TBL] [Abstract][Full Text] [Related]
19. Novel synthetic triterpenoid methyl 25-hydroxy-3-oxoolean-12-en-28-oate induces apoptosis through JNK and p38 MAPK pathways in human breast adenocarcinoma MCF-7 cells.
Rabi T; Banerjee S
Mol Carcinog; 2008 Jun; 47(6):415-23. PubMed ID: 18058803
[TBL] [Abstract][Full Text] [Related]
20. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
